Jim Simons Kintara Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.14 - $6.8 $62,734 - $3.05 Million	-448,100 Reduced 62.03%	274,300 $30,000
Q2 2022 Aug 12, 2022	BUY	$0.14 - $0.5 $93,419 - $333,642	667,284 Added 1210.69%	722,400 $201,000
Q1 2022 May 13, 2022	SELL	$0.31 - $0.55 $45,871 - $81,385	-147,974 Reduced 72.86%	55,116 $22,000
Q4 2021 Feb 11, 2022	BUY	$0.51 - $1.04 $103,575 - $211,213	203,090 New	203,090 $104,000
Q2 2021 Aug 13, 2021	SELL	$1.26 - $2.4 $58,590 - $111,600	-46,500 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$1.32 - $2.74 $7,612 - $15,801	5,767 Added 14.16%	46,500 $81,000
Q4 2020 Feb 10, 2021	SELL	$1.26 - $1.72 $165,262 - $225,596	-131,161 Reduced 76.3%	40,733 $52,000
Q3 2020 Nov 13, 2020	BUY	$0.63 - $1.7 $108,293 - $292,219	171,894 New	171,894 $241,000

Ticker KTRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,807,296
Market Cap $17.8M
Description
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.